Thyrocare Block Deal: ₹1,000 Crore Transaction Planned

Thyrocare Technologies Ltd is set for a significant block deal, involving approximately 1.5 crore shares valued at around ₹1,000 crore. The transaction’s floor price is established between ₹630-631 per share, representing a discount of up to 3% from the stock’s recent closing price.

Key Transaction Details

• Expected Shares: 1.5 crore
• Estimated Value: ₹1,000 crore
• Floor Price Range: ₹630-631 per share
• Discount from Closing: Up to 3%
• BSE Closing Price: ₹649.20
• Daily Increase: Up ₹27.60, or 4.44%

While the seller’s identity remains undisclosed, Thyrocare is strategically expanding its diagnostic offerings. The company recently introduced a GLP-1 weight-loss drug testing package, targeting an emerging market segment.

Growth & Debt Strategy

• CEO Rahul Guha noted a “significant opportunity” in the GLP-1 area, anticipating increased demand for diagnostic testing.
• Future demand is also expected from potential labor regulations mandating health checks for employees over 40.
• The company aims to reduce promoter-level debt and lower its pledged shareholding, currently at 61%.
• A 10% stake was sold earlier this year to partially repay a loan.
• No further stake sales are planned, with other assets to be monetized for debt reduction.

This expected block deal coincides with Thyrocare’s broader efforts to streamline its financial structure and capitalize on new market opportunities. The stock closed strong on the BSE, reflecting market activity around these developments.